Menu

Dr. Giuseppe Giaccone is a medical oncologist, hematologist, associate director for clinical research and co-leader of the Experimental Therapeutics Program at the Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C. He is also a professor of medical oncology and pharmacology in the Department of Oncology at Georgetown University Medical Center.

Dr. Giaccone’s research includes immunotherapy and other targeted therapy options for the treatment of lung cancer tumors and other malignancies of the chest. He is the principle investigator for various clinical trials at the Research Center and studies genetic abnormalities and drug resistance. Dr. Giaccone is also a co-chair for the American Society for Clinical Oncology’s guidelines for advanced non-small cell lung cancer.

Main Speciality: Oncology

Other Interests & Specialties: Oncology, general oncology, internal medicine, hematology, pharmacology, lung cancer and mesothelioma.

Certifications, Awards & Accolades: Co-chair for the American Society for Clinical Oncology’s guidelines for advanced non-small cell lung cancer, Director’s Award from the National Cancer Institute, New Drug Development Office (NDDO) Honorary Award from the NDDO Foundation, Daniel C. Ihde Memorial Lecture Award from the National Cancer Institute, honorary member of the Hellenic and International Society of Molecular-Genomic Medicine and Research. Hellenic and International Society of Molecular-Genomic Medicine and Research

Education & Experience:

  • Medical Degree from the University of Torino Faculty of Medicine
  • Fellowship at the National Cancer Institute
  • Fellowship at the Universita degli Studi di Torino
  • Residency at Universita degli Studi di Torino
  • Internship at Universita degli Studi di Torino

Publications:
30 Immunotherapy in advanced NSCLC-from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)ESMO Open. May 2018;3(4):e000298 doi: 10.1136/esmoopen-2017-000298

Biology and management of malignant pleural mesotheliomaEuropean Journal of Cancer. November 2006;42(16):2706-2714. doi: 10.1016/j.ejca.2006.07.011

Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup StudyJournal of Clinical Oncology. March 2006;24(9):1435-42. doi: 10.1200/JCO.2005.03.3027

Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460Clinical Cancer Research. February 2002;8(2):596-606.

Mesothelioma Clinical Trials by Giuseppe Giaccone

Dr. Giuseppe Giaccone is associated with the following clinical trials:

Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: July 17, 2012

Status: Completed

Photo of Dr. Giuseppe Giaccone

Get Help Contacting Dr. Giuseppe Giaccone


    Privacy policy: All information is secure and will never be released

    TRUSTe

    Free

    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide



      Privacy policy: All information is secure and will never be released

      TRUSTe